Pure Global
NCT06232707

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
Celgene·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Drug/Device/Intervention
Alnuctamab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Celgene
Location
Birmingham,Los Angeles,Stanford,New Haven,New Orleans,Baltimore,Hackensack,Summit,New York,Cincinnati,Cleveland,Providence,Watertown,Dallas,Seattle,Florencio Varela,La Plata,Pilar,Buenos Aires,Liverpo, Argentina,Australia,Austria,Belgium,Brazil,Canada,Chile,China,Czech,France,Germany,Greece,Hungary,In
Timeline & enrollment
Phase
Phase 3
Start date
Mar 13, 2024
End date
Sep 21, 2030
Enrollment
466 participants
Primary outcome

Progression-free Survival (PFS)

Summary

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to
 standard of care regimens in participants with relapsed or refractory multiple myeloma
 (RRMM).

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06232707
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06232707 through Pure Global AI's free database. This Phase 3 trial is sponsored by Celgene and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 466 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.